Overview

Price chart · mood · technical indicators

NXGL

Nexgel Incstock Healthcare

Medical Instruments & Supplies

$0.6176.19%Current Market Mood:Strong Bearish

Market Mood

Price Range (1Y)

$0.56$2.97

Current: $0.61

Market Comparison

vs Healthcare Sector & Medical Instruments & Supplies Industry

NXGL

-76.19%

1Y Performance

Healthcare

Sector 1Y

Medical Instruments & Supplies

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—Forward 1.61

EPS (TTM)$-0.380.0% YoY

Profit margin-26.3%HEALTHCARE

Market cap$4.9MMicro cap

Wall Street coverage

$2.00median target· current $2.20 (-9.1%)1 analyst

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 1.61
PEG ratio: —
P/B: 1.13
P/S (TTM): 0.43
EV/EBITDA: -0.85

Profitability & growth

ROE (TTM): -52.7%
Operating margin: -43.4%
Revenue growth YoY: -8.1%
Dividend yield: —
Beta: 0.74

Last earnings

Apr 1, 2026 · Reported $-0.12

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Nexgel Inc

Company profile

NEXGEL, Inc. manufactures aqueous, electron beam crosslinked, high water content hydrogels and polymeric gels. The company is headquartered in Langhorne, Pennsylvania.

Classification

Sector: Healthcare
Industry: Medical Instruments & Supplies
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 2150 CABOT BOULEVARD WEST, LANGHORNE, PA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$4.9M

Shares outstanding$8.5M

52W high$2.97

52W low$0.56

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

NXGL

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal

NexGel, Inc. 2025 SEC Filing – Executive Compensation, Corporate Governance, Ownership & Audit Disclosure

NEXGEL (NASDAQ: NXGL) hires new CFO to support Celularity deal

Board pay, ownership and new CFO terms at NexGel (NASDAQ: NXGL)

Asymmetry Point LP (NXGL) files Schedule 13G/A showing 8.8% ownership

Langhorne’s Nexgel Transforms Near Disaster into ‘Three-Team Trade’ Acquisition

NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL taps M&A veteran as CFO to steer Celularity integration

NEXGEL Names Ian Blackman As CFO

NEXGEL, INC. Receives Nasdaq Delisting Notice for Failure to Meet Minimum Bid Price Requirement

NexGel Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView News

NexGel receives Nasdaq notice for minimum bid price deficiency

NexGel Receives Nasdaq Deficiency Notice Over Bid Price

NexGel (NASDAQ: NXGL) warned by Nasdaq over sub-$1 share price and delisting risk

NexGel Bets Big With Transformational Acquisition And Financing

NEXGEL Reschedules Shareholder Call, Revises Celularity Financing

Celularity sells biomaterials assets, cuts nearly $13M of debt

NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

About Nexgel Inc

Classification

Company profile

NXGL

Market Comparison

NXGL Market Analysis

Overview

NXGL

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal

NexGel, Inc. 2025 SEC Filing – Executive Compensation, Corporate Governance, Ownership & Audit Disclosure

NEXGEL (NASDAQ: NXGL) hires new CFO to support Celularity deal

Board pay, ownership and new CFO terms at NexGel (NASDAQ: NXGL)

Asymmetry Point LP (NXGL) files Schedule 13G/A showing 8.8% ownership

Langhorne’s Nexgel Transforms Near Disaster into ‘Three-Team Trade’ Acquisition

NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL taps M&A veteran as CFO to steer Celularity integration

NEXGEL Names Ian Blackman As CFO

NEXGEL, INC. Receives Nasdaq Delisting Notice for Failure to Meet Minimum Bid Price Requirement

NexGel Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView News

NexGel receives Nasdaq notice for minimum bid price deficiency

NexGel Receives Nasdaq Deficiency Notice Over Bid Price

NexGel (NASDAQ: NXGL) warned by Nasdaq over sub-$1 share price and delisting risk

NexGel Bets Big With Transformational Acquisition And Financing

NEXGEL Reschedules Shareholder Call, Revises Celularity Financing

Celularity sells biomaterials assets, cuts nearly $13M of debt

NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

About Nexgel Inc

Classification

Company profile

NXGL

Market Comparison